PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.44 - 1.45
1.18 - 2.36
61.0K / 1.73M (Avg.)
-18.00 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
37.14%
Revenue growth above 1.5x 1177.HK's 9.03%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
34.50%
Gross profit growth above 1.5x 1177.HK's 12.02%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-29.21%
Negative EBIT growth while 1177.HK is at 20.68%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
8.25%
Operating income growth under 50% of 1177.HK's 27.41%. Michael Burry would be concerned about deeper cost or sales issues.
-28.65%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-30.77%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-30.77%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.24%
Share reduction more than 1.5x 1177.HK's 5.51%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.24%
Diluted share reduction more than 1.5x 1177.HK's 5.58%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-2.56%
Negative OCF growth while 1177.HK is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-1.94%
Negative FCF growth while 1177.HK is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-3.78%
Negative 10Y revenue/share CAGR while 1177.HK stands at 0.00%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
11301.73%
5Y revenue/share CAGR above 1.5x 1177.HK's 130.22%. David Dodd would look for consistent product or market expansions fueling outperformance.
543.21%
3Y revenue/share CAGR above 1.5x 1177.HK's 50.13%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-154.74%
Negative 10Y OCF/share CAGR while 1177.HK stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
29.96%
OCF/share CAGR of 29.96% while 1177.HK is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-90.57%
Negative 3Y OCF/share CAGR while 1177.HK stands at 133.74%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-552.26%
Negative 10Y net income/share CAGR while 1177.HK is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1545.34%
Negative 5Y net income/share CAGR while 1177.HK is 203.25%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
40.64%
3Y net income/share CAGR above 1.5x 1177.HK's 23.59%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
-13.62%
Negative 5Y equity/share growth while 1177.HK is at 355.64%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-40.12%
Negative 3Y equity/share growth while 1177.HK is at 204.35%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Cut dividends over 10 years while 1177.HK stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-100.00%
Negative 5Y dividend/share CAGR while 1177.HK stands at 33.31%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Firm’s AR is declining while 1177.HK shows 12.47%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
20.44%
Inventory growth well above 1177.HK's 16.78%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-4.34%
Negative asset growth while 1177.HK invests at 1.41%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-8.62%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
24.79%
Debt growth far above 1177.HK's 7.14%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-57.76%
We cut SG&A while 1177.HK invests at 1.97%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.